Glioblastoma Market Snapshot: Two Approvals In 2024 And A Rich Pipeline

Glioblastoma carries a grim prognosis. The biopharma industry is trying to improve patient outcomes, with 120 drugs in the pipeline and two anticipated approvals this year.

Soft and blurry image:Medical image MRI Brain showing There is diameter cystic mass or tumor at Left frontal lobe Glioblastoma at Lt frontal lobe with metastasis, brain metastases.
Biopharma Investments Offer Hope For Glioblastoma Patients • Source: Shutterstock

Patients with glioblastoma can expect to live a median eight months after diagnosis, but two anticipated launches in 2024 and a rich development pipeline could improve that bleak clinical outlook.

“There’s never been so much cause for hope. The standard of care hasn’t changed for 25 years,” Will Jones, chief...

More from Market Intelligence

More from In Vivo

Strategic Surprises: The Drugs That Rewrote The Forecasts

 

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.